Trial · NCT02165397
Adverse events672
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 672
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Ibrutinib + Rituximab | 17 | 75 | |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Rituximab | 21 | 75 | |
| other | Anaemia | Blood and lymphatic system disorders | Open-Label Substudy: Ibrutinib | 5 | 31 | |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Ibrutinib + Rituximab | 9 | 75 | |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Placebo + Rituximab | 2 | 75 | |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Open-Label Substudy: Ibrutinib | 8 | 31 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Ibrutinib + Rituximab | 0 | 75 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Placebo + Rituximab | 0 | 75 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Open-Label Substudy: Ibrutinib | 2 | 31 | |
| other | Neutropenia | Blood and lymphatic system disorders | Ibrutinib + Rituximab | 12 | 75 | |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo + Rituximab | 7 | 75 | |
| other | Neutropenia | Blood and lymphatic system disorders | Open-Label Substudy: Ibrutinib | 9 | 31 | |
| other | Spontaneous haematoma | Blood and lymphatic system disorders | Ibrutinib + Rituximab | 0 | 75 | |
| other | Spontaneous haematoma | Blood and lymphatic system disorders | Placebo + Rituximab | 0 | 75 | |
| other | Spontaneous haematoma | Blood and lymphatic system disorders | Open-Label Substudy: Ibrutinib | 2 | 31 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Ibrutinib + Rituximab | 5 | 75 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo + Rituximab | 8 | 75 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Open-Label Substudy: Ibrutinib | 6 | 31 | |
| other | Atrial fibrillation | Cardiac disorders | Ibrutinib + Rituximab | 11 | 75 | |
| other | Atrial fibrillation | Cardiac disorders | Placebo + Rituximab | 1 | 75 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02165397/events